Sign in
TerminatedPhase 1

Descartes-25 in Relapsed/Refractory Multiple Myeloma

Key facts

Who runs it
Cartesian Therapeutics
Where
Bethesda and Shreveport, United StatesSee the 2 sitesAlso in 1 other country, 1 site
Trial code
Status
Terminated
Phase
Phase 1
People taking part
9 people enrolled
Started
25 Nov 2021
Ended
8 Nov 2024
Type of study
Interventional, 4 groups
Treatments tested
  • Descartes-25
Record updated
12 November 2024
Why it stopped
Phase 1 enrollment completed. Further clinical development terminated.

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • 18 years and older'
  • diagnosed with active R/RMM, who have failed 2 lines of treatment
  • have measurable disease

Who cannot take part

  • Patients with active plasma cell leukemia

Where in United States

Also in 1 other country, 1 site

  • Center for Cancer and Blood DisordersBethesda, United States
  • Louisiana State University Health Science Center at ShreveportShreveport, United States

About the trial

What the trial wants to find out

This is a Phase I/IIa dose-escalation study to evaluate the safety, tolerability, and preliminary efficacy of an allogeneic Mesenchymal Stem Cell (Descartes-25) product secreting a bispecific protein and other proteins in patients with Relapsed/Refractory Multiple Myeloma.

The 4 groups in the trial

  • Arm 1: Dose Level 1Treatment being tested

    Minimum of 3 patients per Dose Level will be treated sequentially with once weekly infusions for 3 weeks in a 28-day cycle until the Maximum Tolerated Dose (MTD) is reached.

    Treatment: Descartes-25

  • Arm 2: Dose Level 2Treatment being tested

    Minimum of 3 patients per Dose Level will be treated sequentially with once weekly infusions for 3 weeks in a 28-day cycle until the Maximum Tolerated Dose (MTD) is reached.

    Treatment: Descartes-25

  • Arm 3: Dose Level 3Treatment being tested

    Minimum of 3 patients per Dose Level will be treated sequentially with once weekly infusions for 3 weeks in a 28-day cycle until the Maximum Tolerated Dose (MTD) is reached.

    Treatment: Descartes-25

  • Arm 4: Dose ExpansionTreatment being tested

    In Arm 2, the MTD established in Arm 1 will be administered for 3 28-day cycles to further evaluate the product's safety and preliminary efficacy.

    Treatment: Descartes-25

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase I/IIa Study of Descartes-25 in Patients With Relapsed/Refractory Multiple Myeloma
Record updated
12 November 2024